Abstract: Acute rejection (AR) remains the biggest challenge during the first year after heart transplantation despite advances in immunosuppressive therapy. The early detection and curbing of AR are crucial to the survival of transplant recipients. However, as the criterion standard for AR, endomyocardial biopsy has several limitations because of its inherent invasiveness and morbidity. Traditional imaging techniques, such as echocardiography and cardiac magnetic resonance imaging, are of certain value for AR, but their diagnostic criteria and accuracy remain in question. Molecular imaging sheds new light on AR diagnosis because it can provide information about gene expression and the location of molecules and cells. This article reviews the latest research and applications of several typical modalities of molecular imaging used in AR and discusses their advantages and disadvantages.
H eart transplantation currently achieves great success in patients with end-stage heart failure. However, acute rejection (AR) after heart transplantation remains the biggest challenge with this life-saving treatment during the first year after transplantation. Approximately 40% of patients will experience at least 1 episode of AR within this period. 1 Furthermore, AR contributes to approximately 12% of the mortalities that occur between 1 and 12 months posttransplantation. 2 Moreover, AR is an independent risk factor for the development of cardiac allograft vasculopathy, an irreversible stage on the path to final allograft dysfunction. Therefore, the early detection and curbing of AR is crucial to the survival of transplant recipients.
At present, endomyocardial biopsy (EB) is the only criterion standard for AR diagnosis. However, as an invasive procedure, routine EB is extremely inconvenient for the patient and is concomitant with several major, albeit rare, complications, such as carotid artery puncture, permanent heart block, and cardiac tamponade. Furthermore, EB has disadvantages including radiation exposure, sample error, myocardial scarring, and venous thrombosis. 3, 4 For this reason, the strategy of performing EB 1 year after transplantation has been questioned, and attempts to reduce its frequency have also been reported. 5 Therefore, a noninvasive and facile evaluation method for the detection of rejection in cardiac transplant patients is highly desirable.
Nowadays, a noninvasive gene expression profiling test (AlloMap, CareDx, Brisbane, CA) has been already well tested and clinically accepted for surveillance after heart transplantation in selected low-risk patients with respect to clinical outcomes. 6 The test is performed on a blood sample, reported as a single score that mainly exclude the likelihood of cellular rejection. The guidelines of International Society of Heart and Lung Transplantation stated that gene expression profiling test can be used to rule out the presence of acute cellular rejection of grade 2R or greater in appropriate low-risk patients, between 6 months and 5 years after heart transplantation. 7 However, The test just excels in regard to a very high negative predictive value. The positive predictive value for cellular rejection is not high. And it cannot apply to other forms of heart rejections, such as antibody-mediated rejection or cardiac allograft vasculopathy. Image technologies that can noninvasively provide visualized information are still needed.
Among many imaging techniques, echocardiography and cardiac magnetic resonance (CMR) imaging are considered the most promising diagnostic techniques to detect AR. Furthermore, some studies have confirmed that the diagnostic accuracy of echocardiography and CMR for assessing the rejection grade of AR is strongly correlated with EB. 8 However, due to methodological heterogeneity, the use of different parameters and cutoff values have led to conflicting outcomes between studies, thus limiting the clinical application of echocardiography and CMR. More importantly, diagnosis using traditional imaging techniques depends on morphological and hemodynamic changes. By the time that these appear, AR has already entered a "relatively serious stage." To achieve better long-term results, diagnosis methods that can be used at earlier stages are urgently required.
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In recent years, molecular imaging has improved greatly and has shed new light on AR diagnosis. Molecular imaging represents the convergence of multiple image-capture techniques, basic cell/molecular biology, chemistry, medicine, pharmacology, medical physics, biomathematics, and bioinformatics into a new imaging paradigm. 9 With the help of specific molecular probes known as biomarkers, we can visualize cellular function and follow molecular processes in vivo, enabling earlier and more precise diagnosis before morphological and hemodynamic damage occur. Molecular imaging is currently applied to the diagnosis of diseases, such as cancer, neurological and cardiovascular disease, and AR.
Many modalities can be used for the noninvasive molecular imaging of AR, such as ultrasound, magnetic resonance imaging (MRI), nuclear imaging, including positron emission tomography (PET) and single photon emission-computed tomography (SPECT), and optical imaging. Each technique has its own strengths and weaknesses, and some are more adept at imaging multiple targets than others. In this article, we attempted to further assess the diagnostic value of several typical molecular imaging modalities for AR. Because most current studies are limited to animals, rarely refer to human (Table 1) . Thus, this review will mainly focus on animal studies.
Ultrasound Molecular Imaging
Ultrasound molecular imaging (UMI) has emerged as a promising noninvasive imaging strategy for assessing biological processes at the molecular level and combines the advantages of ultrasonography (including high spatial and temporal resolution, lack of ionizing irradiation, relatively low cost, and widespread availability in imaging departments throughout the world) with novel molecular-targeted ultrasound contrast agents. 31 Molecular ultrasound contrast agents are microsized or nanosized gas bubbles that are stabilized by a surfactant or polymer coating (Figure 1 ). When high-affinity binding ligands are added onto the bubble shell, molecular ultrasound contrast agents can bind to specific receptors that are involved in various disease processes. After intravenous administration, these targeted ultrasound contrast agents accumulate at tissue sites that overexpress specific molecular markers, thereby enhancing the ultrasound imaging signal.
Weller et al 10 were the first to apply UMI to the detection of acute cardiac transplant rejection. Using anti-intercellular adhesion molecule-1 antibody-conjugated microbubbles (MB ICAM ), the authors assessed the inflammatory status of the endothelium, which plays a pivotal role in the pathogenesis of heart transplant rejection. After intravenous injection, MB ICAM was selectively bound to rejecting versus nonrejecting myocardium, thus enabling the detection of AR. The authors also found that the myocardial video intensity obtained using MB ICAM was significantly higher in a rejecting group (Brown Norway to Lewis strain) than in control groups (Lewis to Lewis or Brown Norway to Brown Norway). Conversely, control myocardium showed little difference between MB ICAM and control MB (conjugated with isotype control antibody) adhesion. ICAM-1-targeted ultrasound signal was strongly correlated with ICAM-1 expression and histological rejection status. However, this study was limited to the extremes of normal and fulminant disease. It remains unknown whether ICAM-1 expression or MB attachment to the molecules parallels rejection severity.
To further study this issue, Kondo et al 11 applied leukocytetargeted MBs for the quantitative assessment of acute cardiac rejection of varying severity. The pattern of signal intensity variation among different severities of AR agreed well with macrophage cell counts, which were correlated with CD3-positive cell (T lymphocyte) counts. BR1, an aqueous suspension of stabilized sulfur hexafluoride bubbles encased by lipid shells, were used as leukocyte-targeted MBs in their study. In a previous study, lipid MB agents were retained within the microcirculation of inflamed tissue due to their attachment to and phagocytosis by activated leukocytes, including macrophages. MBs that interact with leukocytes remain acoustically active and enable the ultrasound imaging of leukocytes that are recruited by reperfusion injury in the kidney and heart. 32, 33 Both of these previous studies focused on inflammatory markers in blood vessels that are also involved in other pathologic conditions, such as ischemia or reperfusion injury, which inevitably occur during heart transplantation. Therefore, the specificity and accuracy of UMI-targeted inflammatory molecular or macrophages for the diagnosis of AR remains unclear. T cells play a central role in graft rejection, and the degree of T cell infiltration is the primary grading standard of AR in clinical heart transplantation. Thus, the infiltration of UMItargeted T cells in rejected myocardium may improve the sensitivity and accuracy of AR diagnosis. However, activated T cells are mainly distributed in the myocardial interstitium outside blood vessels during AR. Widely used ultrasound contrast agents include microsized particles (1-8 μm in diameter), similar to the size of erythrocytes. 34 Therefore, MBs are used only in blood pool imaging modalities because they cannot penetrate blood vessels. To image T cells outside blood vessels, small-sized bubbles are urgently required. The development of nanotechnology in molecular imaging provides a possible solution. Nanoscale bubbles (nanobubbles) that are less than 700 nm in diameter can penetrate the vessel wall, which makes extravascular tissue imaging possible. 35 Nanobubbles are composed of various polymer or phospholipid shells and gas, liquid, or solid cores. Due to the enhanced permeation and retention effects that such bubbles exert at the sites of tumor vascular leaks with pore sizes of up to 780 nm, nanobubbles have been extensively applied in extravascular ultrasonic imaging in various diseases. 36, 37 Wu et al 12 used phospholipid shell and gas core nanobubbles that were loaded with anti-CD25 antibodies that targeted activated T cells for the UMI of AR. Compared with control nanobubbles, CD25-targeted nanobubbles showed a delayed enhancement of myocardium and a second peak in the timeintensity curve. The intensity and time of the second peak were both positively correlated with transplant time and the AR pathologic grade.
Molecular and Cellular MRI
Molecular and cellular MRI is a noninvasive technique for the visualization of molecular and cellular processes in vivo using molecular probes (Figure 2 ). Due to its high spatial resolution, excellent soft tissue contrast and ability to detect and quantify molecular probes, molecular MRI has been used to image cardiovascular morphology, physiology, and molecular events, including AR.
Iron oxide-based contrast agents (Table 1) , such as superparamagnetic iron oxide (SPIO, with particle sizes ranging from >30 to 1000 nm in diameter), ultrasmall SPIO (USPIO, with particle sizes ranging between 10 and 30 nm in diameter) nanoparticles, and microsized iron oxide particles (MPIO, <10 μm), have been used to label and track cells in vivo using T2*-weighted MRI (also termed cellular MRI). Most cellular MRI studies of AR rely on the superior relaxivity of SPIO or USPIO nanoparticles for image contrast. 38, 39 It is thought that SPIO and USPIO particles are taken up by immune cells, mainly by macrophages. Using these agents, macrophages can be labeled in vivo by direct intravenous injection, and the degree of image contrast due to iron oxide-labeled cells correlates well with rejection grade determined by histology.
14 Because of the small particle size, cells must ingest thousands of SPIO or USPIO particles to create a local magnetic field gradient that is detectable by T2*-weighted MRI, especially at the level of a single cell. Each micrometer-sized MPIO can contain picogram quantities of iron and exerts a much greater magnetic susceptibility effect than a smaller particle. Therefore, the loading of 1 or a few MPIO particles into a cell is sufficient for MRI detection. 15, 16 Electron micrograph studies have shown that MPIOs are concentrated by macrophages within membranebound vesicles. The macrophage thus becomes the basic unit of contrast. Individual cells can be easily detected by MRI due to the superparamagnetic iron center, which can propagate a magnetic field gradient over an area as much as 50 times that of the particle radius. 40 Furthermore, cells can not only be labeled in vivo but also ex vivo. 41 The in vivo cell labeling efficiency of iron oxide by direct intravenous injection is low because of particle dilution and accessibility. However, cells can be isolated from a host and labeled with a suitable MRI contrast agent ex vivo in a culture medium. The labeled cells can then be infused into an animal or a human, and their migration can be monitored by MRI. In this way, more contrast agent can be endocytosed by cells, resulting in a higher labeling efficiency. This method is especially suitable for smaller particles, such as SPIO and USPIO particles. Additionally, the labeling of nonspecific cell types can be avoided using an ex vivo procedure. However, ex vivo labeling is complex, requires the isolation of cells, and is challenging for in vivo cell labeling.
Iron oxide-based cellular imaging is very sensitive; however, because this material is a negative contrast agent, the hypointense contrast produced can be confused by intrinsic contrast, image artifacts, or pathologies that also result in negative contrast. Therefore, in some cases, it is difficult to unambiguously assign contrast to labeled cells. Moreover, it is sometimes difficult in practice to robustly quantify the hypointense contrast and regions of signal dropout due to the presence of labeled cells. Due to these limitations, it would be useful to have a cellular imaging agent that provides positive image contrast or positive signal. 17 Gadolinium-based MR probes generate positive contrast in T1 MRI images, which can be detected more easily than the negative contrast generated by iron oxide particles. To conduct molecular or cellular imaging, these new Gd-based MR probes are designed to conjugate a specific vector (eg, small molecules, peptides, or antibodies) with a Gd-chelate. After binding of the probe to its target, a more intense T1 effect can be induced. 42 These probes involve Gd-containing liposomes, 43 lipoproteins, 44 and micelles. 45 However, molecular or cellular MRI for AR that rely on gadolinium-based probes has rarely been reported.
Several techniques have been developed to generate positive contrast with iron oxide cell labeling, such as inversion recovery with ON-resonance water suppression 46 and phase-sensitive techniques that enhance the detectability of iron oxide-labeled cells. 47, 48 However, these techniques may not achieve pervasive application due to the necessity for magnetic preparation pulses and due to difficulties at tissue interfaces or with certain pathologies that involve inherent magnetic susceptibility and image phase differences.
Fluorine agents comprise a class of agents used for cellular MRI that have gained attention in recent years. In contrast to cellular imaging with metal-ion agents, fluorine agents are directly detected. Hitchens et al 17 used a commercially available formulation of perfluoro-15-crown-5-ether to label and detect macrophage accumulation in rat models of cardiac and renal rejection by 19 F MRI. Almost no background signal is present that would need to be distinguished from the labeled cells because very low levels of fluorine are typically found in mammals (mainly as fluoride). This provides the advantage that the signal is highly correlated with labeled cells and is unlikely to be confused with other pathologies or image artifacts. While detecting macrophage accumulation due to rejection, the results of 19 F MRI are generally consistent with iron-oxide cell labeling and T2*-weighted contrast imaging, 15, 49 and these 2 techniques can offer complementary information in many respects. Iron oxide agents offer high sensitivity at high resolution, and 19 F offers unambiguous detection and a more easily quantified signal.
Most strategies used so far have mainly focused on macrophages rather than T cells. For example, as a prevalent agent used in cellular MRI, SPIO/USPIO particles are taken up mainly by macrophages and are not taken up to the same extent by T cells. 50 In theory, cellular MRI using iron-oxide agents reflects mainly macrophage-related changes in graft rejection. Thus, ways must be found to enhance the incorporation of these MRI contrast agents into T cells. The conjugation of specific targeting vectors (eg, small molecules, peptides, or antibodies) with MRI contrast agents may be a favorable choice. CD3 antigen is a universal marker for T cells. Guo et al 13 developed a MRI-visible and CD3 antibody(scAbCD3)-targeted multifunctional polymeric nanocarrier containing SPIO for the detection of T cells in AR and gene delivery (Figure 3 ). Lewin and Dodd 51,52 prepared a new composite particle by conjugating a peptide from the transactivator protein (Tat) of HIV-1 to cross-linked aminated dextrancoated iron oxide particles. The Tat peptide has been shown to promote the translocation of various "cargos" through the plasma membrane of a variety of cells, including T cells. 53 The receptor-mediated endocytosis pathway is another approach that can be used to increase the incorporation of MR contrast agents into cells. Ahrens et al 54 conjugated an anti-CD11c monoclonal antibody (mAb) to commercially available SPIO particles and then incubated the resulting particle conjugates with bone marrow-derived dendritic cells (DCs) or with a fetal skin-derived DC line in culture media. These cells exhibited an approximately 50-fold increase in uptake relative to DCs that were incubated with SPIO particles without the mAb; importantly, this labeling procedure did not affect the immunological function of the cell. The authors further reported that when these labeled DCs were injected into murine quadriceps and then monitored in vivo for several days using MRI at 11.7 T, the SPIO-labeled DCs remained within the muscle cells for longer than 24 hours. The receptormediated endocytosis pathway may provide a good way to label T cells for use in cellular MRI. 
Nuclear Imaging
Nuclear medicine is the main application of molecular and cellular imaging in current clinical use. PET and SPECT are the main molecular imaging modalities. The strengths of nuclear imaging are its high sensitivity and the availability of a wide variety of targeted, radioactively labeled tracers in experimental and clinical applications. 55 Heart transplant rejection is characterized pathologically by myocyte necrosis and interstitial mononuclear cell infiltrationassociated apoptosis. Either of these components can be targeted for the noninvasive detection of transplant rejection (Figure 4) . A body of research from the 1980s and 1990s explored the use of radionuclide scintigraphy for the noninvasive detection of cardiac allograft rejection. Eisen In-labeled lymphocytes for diagnosing AR in human subjects was confirmed by Rubin et al 20 Additionally, 99m technetiumlabeled annexin-V (a marker of apoptosis), 23, 24 oligonucleotides against interleukin-2 mRNA, 22 and anti-sialoadhesin mAb (a marker of inflammatory macrophages) have been used for the detection of AR ( Figure 5 ). 21 Currently, the leading molecular imaging modality is PET. The spatial resolution of PET is higher than that of SPECT (4-5 vs 10-16 mm with clinical scanners). Furthermore, attenuation (the quantifiable reduction in the number of events present at the face of the detector due to absorption or scattering through tissues) of the emitted radiation in PET can be precisely corrected because the total length through the FIGURE 3. A, A schematic diagram of the therapeutic process of magnetic targeting polyplex scAbCD3-PEG-g-PEI-SPIO. B, MRI of a transplantation model during the period from 0 to 10 days after transplantation. Areas marked with dashed red, purple, and green circles illustrate the grafted hearts in the animals with different treatments. TN, scAbCD3-PEG-g-PEI-SPIO/pDNA treatment; NN, PEG-g-PEI-SPIO/pDNA treatment; TD, scAbCD3-PEG-g-PEI-SPIO/pDNA-DGKR treatment; NH, native hearts. C, NIRF imaging of the transplantation model during the tenth day after transplantation. D, MRI signal intensity change in the transplanted heart during the period from 0 to 10 days after transplantation (*P < 0.05, compared with NH). E, Prussian blue staining and histological CD3 antibody analysis of the graft tissues from the TN, NN, TD groups, and NH (magnification, 100Â) on the third day after transplantation. Positive Prussian blue staining is shown in blue, and positive CD3 immunohistochemical staining is shown in brown. NIRF, near-infrared fluorescence. Reprinted with permission from Guo Y, Chen W, Wang W, et al. Simultaneous diagnosis and gene therapy of immuno-rejection in rat allogeneic heart transplantation model using a T-cell-targeted theranostic nanosystem. ACS Nano. 2012;6:10646-10657. 13 Copyright 2012, American Chemical Society.
body determines the attenuation factor along a coincidence line. Therefore, PET is a more robust technique than SPECT for imaging most molecular events. N]NH3 PET imaging, which reflects myocardial blood flow, this method can be used as a noninvasive, quantitative technique for the serial monitoring of allograft rejection and has potential application in human transplant recipients. However, due to the immune responses that coincide with ischemia-reperfusion injury and the working condition of the heart, the basal myocardial uptake of [ 18 F]FDG is variable, and this may ultimately affect the ability of this technique to detect rejection. 58, 59 Another means of enhancing the resolution of these technologies is to use multiple modalities. The simplest manifestation of this is the coregistration of images obtained low-resolution techniques (for example, PET) with highresolution anatomical images (such as those obtained, for example, using CT or MRI) obtained in the same session. Thus, functional imaging by PET or SPECT, which depicts the spatial distribution of metabolic or biochemical activity in the body, can be more precisely aligned or correlated with anatomical images obtained using CT or MRI. Ueno et al 26 detected macrophage infiltration in cardiac mouse allografts using copper-64-derivatized dextran nanoparticle PET/CT imaging. The authors also demonstrated that this method can be used to monitor therapeutic immunomodulation in mice with total allomismatched hearts. Although much evidence has shown the reliability of molecular imaging for AR detection by PET or SPECT, these techniques are considered to decrease but not eliminate the need for protocol biopsies. It is likely that a negative PET or SPECT scan could allow for a decreased biopsy frequency, whereas a positive PET or SPECT scan would trigger a biopsy. Furthermore, exposure to ionizing radiation is a limitation that might play an important role in the screening of asymptomatic individuals or in repeated, follow-up imaging. Furthermore, it should be noted that the animal model most commonly used in AR research is heterotopic transplantation into the abdominal cavity; this model results in a beating but nonworking heart that contacts the peritoneum. Therefore, translating results from this model to heart transplantation requires caution.
Optical Molecular Imaging
Currently, optical molecular imaging (OMI) has become one of the most widely used molecular imaging techniques. With the use of specific molecular markers (such as luciferase and fluorescent proteins), OMI has been applied to imaging fundamental biological processes in vivo, such as in pathogenesis research, gene expression regulation and activity detection, cytological detection, pharmaceutical effect evaluation and efficacy evaluation ( Figure 6 ). 60 OMI includes a variety of imaging modalities, such as bioluminescent imaging (BLI), fluorescence imaging (FI), optical coherence tomography, bioluminescent tomography, fluorescence molecular tomography (FMT), laser speckle imaging, polarization imaging, fluorescence reflectance imaging, diffuse optical tomography, fluorescence resonance imaging, and near-infrared fluorescence. 61 BLI and FI are the most commonly used OMI techniques.
The first approach to detecting allograft rejection in mice using an optical technique involved bioluminescence imaging. Tanaka and colleagues 62 used in vivo BLI to visualize changes in cardiac allograft viability and donor-derived passenger CD5+ cells that occurred in response to cardiac allografting during AR. The authors found that 4 days after transplantation, the intensity of light emitted from cardiac allografts declined in a manner that was correlated with graft beating scores. Furthermore, the light signal from CD5+ passenger leukocytes peaked at 6 hours and as decreased at 12 hours in allograft recipients, whereas the signal remained high until 10 days after transplantation in syngeneic recipients. This research showed that BLI is a useful modality for the quantitative assessment of in vivo cardiac graft viability and the tracking of passenger leukocytes in vivo during AR. Unlike the use of graft beating score, which assesses only whether the cardiac allograft is beating or not, BLI can assess cardiac graft viability and is more suitable for determining cardiac graft survival.
NF-κB is a potent proinflammatory signal transduction molecule that plays a key role in regulating the expression of multiple chemokine and cytokine genes that are involved in innate and adaptive immune responses. 27 Ma and coworkers 63 used BLI to detect NF-κB activation in a cardiac transplantation mouse model and tissue ischemia-reperfusion injury. The results that they obtained showed that luciferase activity was significantly increased in the cardiac allografts and was reduced after CD154 mAb therapy. This study indicated that BLI may be a viable approach to noninvasively and quantitatively visualize NF-κB activation within passenger leukocytes and recipient lymphocytes in a cardiac transplantation mouse model.
FI is another optical technique that has been used in AR. Christen et al 64 injected allograft recipient mice with a quenched fluorescent substrate reporter for cysteinyl proteases, which are expressed abundantly by leukocytes that accumulate in allografts. In vivo FMT imaging of the macrophage response is correlated closely with gradually increasing allograft rejection and attenuated rejection in recipients with a genetically impaired immune response that results from a deficiency in recombinase-1 (RAG-1 −/− ), indicating that fluorescence molecular imaging can noninvasively detect protease activity in cardiac allograft rejection and has translational potential.
The advantages of OMI include high specificity and sensitivity, use of nonionizing radiation, and the ability to label many important genes and proteins. However, the overall low spatial resolution and limited penetration depth of optical imaging signals has limited its clinical application. New approaches, such as FMT, which allows the volumetric reconstruction of the source of fluorescent light, can improve spatial resolution to 1 mm at the surface to 3 mm in the center of small animals. 28 However, this technique is insufficient for human cardiac imaging. Near infrared imaging may be an applicable choice because the wavelength used ranges from 650 to 900 nm, which can in theory penetrate 7 to 14 cm of tissue. 30 However, the spatial resolution remains to be improved. Furthermore, similar to nuclide imaging techniques such as SPECT and PET, it is difficult to obtain structural images of biological tissue.
CONCLUSIONS
Molecular and cellular imaging has shown great potential for transplantation. The common modalities of molecular and cellular imaging, including magnetic, optical, nuclear, and ultrasound methods, applied to different cellular and molecular targets all allow the detection of allograft rejection. However, each of these methods has strengths and weaknesses. The sensitivities of nuclear imaging and OMI are high, but the spatial resolution is low. MRI and ultrasound methods have high spatial resolution and excellent soft tissue contrast, but the inherent sensitivity is limited. It remains unclear which approach represents the best technique for diagnosing AR.
Until now, some of these techniques have been applied in humans. For example, nuclear imaging techniques using multiple tracers have strong advantages in terms of AR imaging in clinical practice. Additionally, iron oxide nanoparticles have achieved approval for human use in some countries, and cardiac MRI combined with iron oxide contrast agents seems readily transferable to the clinical diagnosis of AR. The 2015 European Association of Cardiovascular Imaging/ Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation stated that "A range of molecular components of acute graft rejection has been targeted with radionuclide scintigraphy." 65 However, this technique is only recommended in clinical practice for patients who are unsuitable for stress echocardiography due to conflicting results in published studies and a lack of availability of large multicenter trial results.
In the future, multiple imaging modalities that combine the advantages of different techniques may be one of development trends. And the development of a multifunctional contrast agent fit for several imaging modalities may be a key problem. Thus, there is a need for chemists to develop contrast agents, for physicists to refine the imaging process, and for mathematicians to improve data analysis and handling. What is more, large clinical trials with multiple centers documenting the diagnostic and prognostic value of these techniques are imperatively needed.
